Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended	6 Months Ended
Jun. 30, 2016	Jun. 30, 2015	Jun. 30, 2016	Jun. 30, 2015
Income Statement [Abstract]
Net sales	$ 1,227,247	$ 277,353	$ 2,868,275	$ 565,630
Cost of sales	700,977	89,503	2,038,919	163,719
Gross Profit	526,270	187,850	829,356	401,911
Compensation and related expenses	475,056	114,774	715,511	200,164
Professional fees	125,359	26,314	194,674	61,822
General and administrative expenses	79,487	63,932	177,899	149,261
Total operating expenses	679,902	205,020	1,088,084	411,247
Operating (Loss)	(153,632)	(17,170)	(258,728)	(9,336)
Interest (expense)	(2,750)	(8,158)	(5,813)	(18,626)
Net (Loss) Before Taxes	(156,382)	(25,328)	(264,541)	(27,962)
Deferred income tax benefit		4,300		8,600
Net (Loss)	(156,382)	(21,028)	(264,541)	(19,362)
Net Income (Loss) attributable to noncontrolling interests	43,594		(2,516)
Net (Loss) attributable to Immudyne, Inc.	$ (199,976)	$ (21,028)	$ (262,025)	$ (19,362)
Basic and diluted (loss) per share attributable to Immudyne, Inc.	$ (0.01)	$ 0.00	$ (0.01)	$ 0.00
Average number of common shares outstanding
Basic	32,338,946	30,650,000	32,174,661	30,204,973
Diluted	$ 32,338,946	$ 30,650,000	$ 32,174,661	$ 30,204,973

Represents the expense recognized during the period arising from equity-based compensation arrangements and related expenses (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.

No definition available.